H-1 Contribute to medical treatment
In order to provide the joy of good health to more people, the MCHC Group seeks to contribute to the treatment of disease* by developing new drugs for disorders that are highly difficult to treat, especially disorders that leverage the Group’s strengths, such as autoimmune disease, diabetes, and kidney disease. We will also spread and disseminate high-quality information that meets the needs of doctors and pharmacists.
* Contribution to the Treatment of Disease
MCHC defines this as follows: The degree of contribution to medical treatment = The degree of difficulty to treat diseases multiplied by the number of administered patients
Mitsubishi Tanabe Pharma CorporationImusera drug adherence program* to treat multiple sclerosis
Mitsubishi Tanabe Pharma Corporation began marketing the pharmaceutical Imusera for patients with multiple sclerosis in November 2011. Since the disease requires long-term care, it is important to provide the patients with psychological support and also measures to prevent them from forgetting to take their medication. Mitsubishi Tanabe Pharma Corporation started the Imusera Hills adherence program in cooperation with outside medical staff. Imusera Hills contributes to the treatment by providing notifications about appropriate usage, safety information, and dosing time via mobile phone and their website.
* Adherence Program
Patients actively participate in treatment policy decisions and treatments are carried out and continued in line with those decisions.
H-2 Contribute to improvements of QOL
QOL generally refers not only to material abundance such as money and goods, but also to a way of thinking which perceives things in qualitative terms including spiritual wealth and satisfaction. The MCHC Group contributes to raising patients’ QOL by offering more treatment options to those who suffer from disease and providing them with easy-to-take medicines.
Mitsubishi Tanabe Pharma CorporationThe new type-2 diabetes agent CANAGLU (canagliflozin hydrate) received the Pharmaceutical Society of Japan Award for Drug Research and Development 2014
SGLT2 inhibitor CANAGLU (generic name: canagliflozin hydrate), discovered by Mitsubishi Tanabe Pharma Corporation, received the Pharmaceutical Society of Japan Award for Drug Research and Development 2014. CANAGLU possesses a new mechanism of action that promotes the excretion of excess glucose into the urine. CANAGLU (canagliflozin hydrate) provides new options in the treatment of type 2 diabetes. Mitsubishi Tanabe Pharma Corporation will co-promote CANAGLU (canagliflozin hydrate) with Daiichi Sankyo with the aim of achieving the No. 1 presence in the field of type 2 diabetes.
H-3 Contribute to early detection and prevention of diseases
Vaccinations are very effective for protection against infectious diseases including influenza and measles. Mitsubishi Tanabe Pharma Corporation also puts effort into the vaccine business and has developed a 4-in-1 vaccine jointly with The Research Foundation for Microbial Disease of Osaka University. Mitsubishi Tanabe Pharma Corporation sells the 4-in-1 vaccine under the name TETRABRIK. The MCHC Group is aiming to increase the index of vaccine treatment* by 17% compared with fiscal 2009.
* Index of vaccine treatment: Since vaccines range in type from those whose effects last for only one season to those whose effects are life-long, this index,which is the original of MCHC, is corrected so that such differences will be evaluated in an appropriate way.
Diagnostic tests* and physical checkups are effective means for early detection of diseases. In addition, diagnostic tests assist in the decision of treatment plans, and physical checkups provide opportunities to review our daily lives to maintain and promote health.
LSI Medience Corporation (formerly Mitsubishi Chemical Medience Corporation) provides testing and analysis services through diagnostic testing for medical institutions and development and manufacturing of in-vitro diagnostic reagents and instruments.
Through the business of LSI Medience Corporation, the MCHC Group has set the target of increasing the number of patients receiving diagnostic tests and the number of people undergoing physical checkups by 26% in fiscal 2015 compared with fiscal 2009.
* Diagnostic tests: Taking specimens of blood, urine, etc. from patients and examining them chemically and morphologically (laboratory tests)